Lupus
The Disease
Systemic lupus erythematosus (SLE) is a multifactorial chronic autoimmune disease, marked by the presence of autoantibodies to nuclear antigens. It is characterized by circulating immune complexes that deposit in tissues, leading to multiorgan damage, with kidneys and skin primarily affected.
IL23
Interleukin-23 (p19 and p40 subunits) is a crucial cytokine implicated in chronic inflammation and autoimmunity, associated with various diseases like psoriasis, psoriatic arthritis, and systemic lupus erythematosus (SLE). IL23 has emerged as a promising therapeutic target for chronicinflammatory and autoimmune diseases.
Evaluation Platforms
TghIL23A mice expressing deregulated human IL23A, develop lupus like pathology with cutaneous involvement and can be treated with protocols standardized for the evaluation of therapeutics.
Read-Out Parameters
In vivo skin pathology scoring
Urine analysis
Circulating IgG levels
Competitive Advantage
TghIL23A model efficiently recapitulates human lupus pathology and in combination to standardized evaluation procedures it offers the opportunity for reliable evaluation of the efficacy of anti-human IL23p19 biologics and biosimilars as well as novel lupus treatments.
